Brexucabtagene autoleucel

Tecartus

Dispersione per infusioneItalyAuthorised

In other countries

The same active substances on other registers, the same brand first.

TecartusBrazil · Gilead Sciences Farmaceutica do Brasil LtdaSame brand
TecartusCanada · 100000000 CELLS / BAG · Suspension · Gilead Sciences Canada INCSame brand
TecartusCanada · 200000000 CELLS / BAG · Suspension · Gilead Sciences Canada INCSame brand
TECARTUS 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSIONSpain · 1 × 10e6 a 2 x 10e6 CELULAS · dispersion para perfusion · Kite Pharma Eu B.V.Same brand
TecartusEuropean Union · Kite Pharma EU B.V.Same brand
TecartusCroatiaSame brand
Tecartus 0.4-2.0 x 10^8 cellen, dispersie voor infusieNetherlands · Oplossing voor infusie · Kite Pharma EU B.V.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Brexucabtagene autoleucel

Tecartus

Dispersione per infusioneItalyAuthorised

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

TecartusUnited States · 210^6 CAR-positive viable T cells per kg body weight · For Injection · Kite Pharma, Inc.

Packs

Pack	Code	Status
0.4 X 10 ALL'OTTAVA - 2.0 X 10 ALL'OTTAVA CELLULE - DISPERSIONE PER INFUSIONE - USO ENDOVENOSO - SACCA (EVA) 68 ML - 1 SACCA	049148012	Autorizzata

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Brexucabtagene autoleucel
Dosage form: Dispersione per infusione
Register: Italy (AIFA)
Status: Authorised
Status in the register: Autorizzata
Registration: AIC 049148
Marketing authorisation holder: Kite Pharma Eu B.V.
ATC code: L01XL06
Group: Antineoplastic and immunomodulating agents
Procedure: Procedura Centralizzata
Supply: Medicinali soggetti a prescrizione medica limitativa, utilizzabili esclusivamente in ambiente ospedaliero o in una struttura ad esso assimilabile